From 92a935f75348941af39facced4ec21c03a1cdbf3 Mon Sep 17 00:00:00 2001 From: mukesh13 Date: Thu, 21 Aug 2025 10:21:32 +0530 Subject: [PATCH] UI styling update --- .../PackagingShipping/DNASamples.jsx | 2 +- .../PackagingShipping/GeneralGuidelines.jsx | 2 +- .../PackagingShipping/PackagingGuideline.jsx | 2 +- .../PackagingShipping/RNASamples.jsx | 72 ++++++++++------- .../PackagingShipping/ShippingSchedule.jsx | 2 +- .../ShippingTemperatureTable.jsx | 2 +- .../SampleGuideline/ContentSection.jsx | 2 +- .../SampleGuideline/GeneralGuidelines.jsx | 76 ++++++++++-------- .../SampleGuideline/IntroSection.jsx | 10 +-- .../SearchSampleRequirements.jsx | 2 +- .../SampleInitiation/ProcessSection.jsx | 4 +- .../SampleInitiation/ProcessSteps.jsx | 6 +- .../SampleInitiation/SampleInitiationPage.jsx | 4 +- app/dna-sequencing/components/AboutDNA.jsx | 9 +-- app/dna-sequencing/components/DNATable.jsx | 12 +-- app/health/Components/ClinicalAreas.jsx | 4 +- app/health/Components/HealthIntro.jsx | 72 ++++++++--------- app/health/Components/HealthTitle.jsx | 2 +- app/health/components/ClinicalAreas.jsx | 4 +- app/health/components/HealthIntro.jsx | 72 ++++++++--------- app/health/components/HealthTitle.jsx | 2 +- .../Components/HereditaryCancerPanel.jsx | 45 ++++++----- .../oncology/Components/OncologyIntro.jsx | 73 +++++++++++------ .../components/HereditaryCancerPanel.jsx | 45 ++++++----- .../oncology/components/OncologyIntro.jsx | 73 +++++++++++------ .../components/ClinicalAreasGrid.jsx | 4 +- .../components/OperifyExome.jsx | 42 +++++----- .../components/OperifyExomeMito.jsx | 72 ++++++++--------- .../rare-disorders/components/RareIntro.jsx | 41 +++++++--- .../components/SampleRequirements.jsx | 73 ++++++++++------- .../components/SolutionsOffer.jsx | 25 ++++-- .../rare-disorders/components/WESInfo.jsx | 36 +++++---- app/rna-sequencing/components/AboutRNA.jsx | 7 +- app/rna-sequencing/components/RNATable.jsx | 4 +- public/images/icons/clock.png | Bin 0 -> 10492 bytes public/images/icons/sample.png | Bin 0 -> 14542 bytes 36 files changed, 501 insertions(+), 402 deletions(-) create mode 100644 public/images/icons/clock.png create mode 100644 public/images/icons/sample.png diff --git a/app/components/PackagingShipping/DNASamples.jsx b/app/components/PackagingShipping/DNASamples.jsx index 8c61468..9d1c536 100644 --- a/app/components/PackagingShipping/DNASamples.jsx +++ b/app/components/PackagingShipping/DNASamples.jsx @@ -5,7 +5,7 @@ const DNASamples = () => { return (
-

Shipping of DNA Samples

+

Shipping of DNA Samples

diff --git a/app/components/PackagingShipping/GeneralGuidelines.jsx b/app/components/PackagingShipping/GeneralGuidelines.jsx index 32bd1d9..c428d3f 100644 --- a/app/components/PackagingShipping/GeneralGuidelines.jsx +++ b/app/components/PackagingShipping/GeneralGuidelines.jsx @@ -4,7 +4,7 @@ const GeneralGuidelines = () => { return (
-

General Guidelines

+

General Guidelines

diff --git a/app/components/PackagingShipping/PackagingGuideline.jsx b/app/components/PackagingShipping/PackagingGuideline.jsx index 6492904..0f3c7f8 100644 --- a/app/components/PackagingShipping/PackagingGuideline.jsx +++ b/app/components/PackagingShipping/PackagingGuideline.jsx @@ -4,7 +4,7 @@ const PackagingGuideline = () => { return (
-

Packaging Guideline

+

Packaging Guideline

diff --git a/app/components/PackagingShipping/RNASamples.jsx b/app/components/PackagingShipping/RNASamples.jsx index 73ad98d..ba730bb 100644 --- a/app/components/PackagingShipping/RNASamples.jsx +++ b/app/components/PackagingShipping/RNASamples.jsx @@ -4,40 +4,50 @@ const RNASamples = () => { return (
-

Shipping of RNA Samples

+

Shipping of RNA Samples

-

- Bioanalyzer QC report is advised to be shared from the client's end, in the - absence of which an agarose Gel Electrophoresis and Nanodrop quantification - to confirm the integrity of RNA must be shared. Samples with A260/280 ratio - values of ~1.8 are considered "pure" for DNA and will be accepted for - processing further. -

- -

- We require Bioanalyzer traces (or similar) for all customer-submitted - sequencing libraries and total RNA samples. If traces are not provided, we - will perform Bioanalyzer QC for an additional fee. If you can supply traces, - please include them into the shipment in hard copy. Also, ensure that your - samples meet the specified sample or library requirements [LINK]. -

- -

- For large-scale projects, RNA samples can be submitted in strip tubes with - individually attached RNase-free caps. Pack the strips into racks (e.g., - empty pipet tip boxes) and ensure they are secured to prevent movement - during transport. -

- -

- RNA, cells, bacteria, and frozen tissue samples should be stored in liquid - nitrogen for rapid freezing and then transported with dry ice. For longer - shipments, RNA samples can also be successfully shipped dry at room - temperature after LiCl/ethanol precipitation and ethanol washes; make sure - to mark the pellet's position on the tubes. -

+
    +
  • + + Bioanalyzer QC report is advised to be shared from the client's end, in the + absence of which an agarose Gel Electrophoresis and Nanodrop quantification + to confirm the integrity of RNA must be shared. Samples with A260/280 ratio + values of ~1.8 are considered "pure" for DNA and will be accepted for + processing further. + +
    • + +
  • + + We require Bioanalyzer traces (or similar) for all customer-submitted + sequencing libraries and total RNA samples. If traces are not provided, we + will perform Bioanalyzer QC for an additional fee. If you can supply traces, + please include them into the shipment in hard copy. Also, ensure that your + samples meet the specified sample or library requirements [LINK]. + +
    • + +
  • + + For large-scale projects, RNA samples can be submitted in strip tubes with + individually attached RNase-free caps. Pack the strips into racks (e.g., + empty pipet tip boxes) and ensure they are secured to prevent movement + during transport. + +
    • + +
  • + + RNA, cells, bacteria, and frozen tissue samples should be stored in liquid + nitrogen for rapid freezing and then transported with dry ice. For longer + shipments, RNA samples can also be successfully shipped dry at room + temperature after LiCl/ethanol precipitation and ethanol washes; make sure + to mark the pellet's position on the tubes. + +
    • +
); diff --git a/app/components/PackagingShipping/ShippingSchedule.jsx b/app/components/PackagingShipping/ShippingSchedule.jsx index 28579b2..55f0240 100644 --- a/app/components/PackagingShipping/ShippingSchedule.jsx +++ b/app/components/PackagingShipping/ShippingSchedule.jsx @@ -4,7 +4,7 @@ const ShippingSchedule = () => { return (
-

Shipping Schedule and Address

+

Shipping Schedule and Address

diff --git a/app/components/PackagingShipping/ShippingTemperatureTable.jsx b/app/components/PackagingShipping/ShippingTemperatureTable.jsx index 1b8b6b2..fbc7270 100644 --- a/app/components/PackagingShipping/ShippingTemperatureTable.jsx +++ b/app/components/PackagingShipping/ShippingTemperatureTable.jsx @@ -129,7 +129,7 @@ const ShippingTemperatureTable = () => { return (
-

Shipping Temperature and Condition

+

Shipping Temperature and Condition

diff --git a/app/components/SampleGuideline/ContentSection.jsx b/app/components/SampleGuideline/ContentSection.jsx index 9165d3c..76a8022 100644 --- a/app/components/SampleGuideline/ContentSection.jsx +++ b/app/components/SampleGuideline/ContentSection.jsx @@ -18,7 +18,7 @@ const ContentSection = () => { return (
-
+
{/* LEFT SIDEBAR */}
diff --git a/app/components/SampleGuideline/GeneralGuidelines.jsx b/app/components/SampleGuideline/GeneralGuidelines.jsx index 7724a93..2ab3934 100644 --- a/app/components/SampleGuideline/GeneralGuidelines.jsx +++ b/app/components/SampleGuideline/GeneralGuidelines.jsx @@ -4,46 +4,58 @@ const GeneralGuidelines = () => { return (
-

General Guidelines

+

General Guidelines

-
    -
  • - Please complete the Sample Initiation Form (SIF), ensuring that the - sample names on the form match the labels on the sample tubes. We also - request that you send an electronic copy of the form and any required QC - data via email. +
      +
    • + + Please complete the Sample Initiation Form (SIF), ensuring that the + sample names on the form match the labels on the sample tubes. We also + request that you send an electronic copy of the form and any required QC + data via email. +
      • -
    • - Each tube should be labeled on the lid with a maximum of 4-6 - alphanumeric characters (e.g., 4B0001). Use a black permanent marker to - write sample names on the top and side of each tube. Avoid writing - directly on the tube wall or cover with an oil pen. +
    • + + Each tube should be labeled on the lid with a maximum of 4-6 + alphanumeric characters (e.g., 4B0001). Use a black permanent marker to + write sample names on the top and side of each tube. Avoid writing + directly on the tube wall or cover with an oil pen. +
      • -
    • - DNA can be submitted in DNase-free water, Elution Buffer, or 10mM Tris - pH 8.0. DNA samples should have an OD260/280 ratio as close to 1.8~2.0 - as possible. All DNA should be RNase-treated and free from degradation - or contamination. Ship with ice packs. The total amount of DNA required - depends on the specific application. +
    • + + DNA can be submitted in DNase-free water, Elution Buffer, or 10mM Tris + pH 8.0. DNA samples should have an OD260/280 ratio as close to 1.8~2.0 + as possible. All DNA should be RNase-treated and free from degradation + or contamination. Ship with ice packs. The total amount of DNA required + depends on the specific application. +
      • -
    • - RNA can be submitted in RNase-free water, RNA Stabilization Reagent, or - 10mM Tris pH 8.0. All total RNA samples should be DNA-free, with an OD - A260/A280 ratio ≥ 1.8, A260/230 ratio ≥ 1.8, and a RIN ≥ 6. Ship with - dry ice. The total amount of RNA required depends on the specific - application. For Long Read Sequencing, RNA samples should have a RIN ≥ - 8. +
    • + + RNA can be submitted in RNase-free water, RNA Stabilization Reagent, or + 10mM Tris pH 8.0. All total RNA samples should be DNA-free, with an OD + A260/A280 ratio ≥ 1.8, A260/230 ratio ≥ 1.8, and a RIN ≥ 6. Ship with + dry ice. The total amount of RNA required depends on the specific + application. For Long Read Sequencing, RNA samples should have a RIN ≥ + 8. +
      • -
    • - The listed concentrations should be determined by fluorometry (e.g., - PicoGreen/Qubit/RiboGreen). If using spectrophotometry (e.g., Nanodrop), - increase concentrations by approximately twofold. +
    • + + The listed concentrations should be determined by fluorometry (e.g., + PicoGreen/Qubit/RiboGreen). If using spectrophotometry (e.g., Nanodrop), + increase concentrations by approximately twofold. +
      • -
    • - The quality inspection method for the sizes and concentrations of the - Ready To Run Library is Qubit and Agilent Bioanalyzer. +
    • + + The quality inspection method for the sizes and concentrations of the + Ready To Run Library is Qubit and Agilent Bioanalyzer. +
diff --git a/app/components/SampleGuideline/IntroSection.jsx b/app/components/SampleGuideline/IntroSection.jsx index 5db1a60..1a3fb95 100644 --- a/app/components/SampleGuideline/IntroSection.jsx +++ b/app/components/SampleGuideline/IntroSection.jsx @@ -2,11 +2,11 @@ import React from 'react'; const IntroSection = () => { return ( -
-
-
-
-

+

+
+
+
+

We humbly offer a wide range of services, including genomics, transcriptomics, metagenomics, epigenomics, single-cell sequencing, genotyping, microarray, bioinformatics, and more. To help us deliver the best results for you, we request you to diff --git a/app/components/SampleGuideline/SearchSampleRequirements.jsx b/app/components/SampleGuideline/SearchSampleRequirements.jsx index 3dbcee9..8e9cf87 100644 --- a/app/components/SampleGuideline/SearchSampleRequirements.jsx +++ b/app/components/SampleGuideline/SearchSampleRequirements.jsx @@ -67,7 +67,7 @@ const SearchSampleRequirements = () => { return (

-

Search Sample Requirements

+

Search Sample Requirements

{ return (
-
+
{/* Main Title */}
-

+

Welcome to Our Online Submission Portal!

diff --git a/app/components/SampleInitiation/ProcessSteps.jsx b/app/components/SampleInitiation/ProcessSteps.jsx index 52d2f0d..88c5798 100644 --- a/app/components/SampleInitiation/ProcessSteps.jsx +++ b/app/components/SampleInitiation/ProcessSteps.jsx @@ -46,8 +46,10 @@ const ProcessSteps = () => {
    {step.items.map((item, index) => ( -
  • - {item} +
  • + + {item} +
    • ))}
diff --git a/app/components/SampleInitiation/SampleInitiationPage.jsx b/app/components/SampleInitiation/SampleInitiationPage.jsx index 6887741..29bdbcc 100644 --- a/app/components/SampleInitiation/SampleInitiationPage.jsx +++ b/app/components/SampleInitiation/SampleInitiationPage.jsx @@ -1,14 +1,14 @@ import React from 'react'; import PageTitle from './PageTitle'; import ProcessSection from './ProcessSection'; -import ContactNote from './ContactNote'; +// import ContactNote from './ContactNote'; const SampleInitiationPage = () => { return (
- + {/* */}
); }; diff --git a/app/dna-sequencing/components/AboutDNA.jsx b/app/dna-sequencing/components/AboutDNA.jsx index 2ed1b6c..41d137c 100644 --- a/app/dna-sequencing/components/AboutDNA.jsx +++ b/app/dna-sequencing/components/AboutDNA.jsx @@ -4,24 +4,21 @@ import React from 'react'; const AboutDNA = () => { return (
-
-

+
+

About DNA Sequencing

Exploring Life's Blueprint with Every Sequence

-
+

DNA sequencing is a method used to determine the precise order of nucleotides (adenine, thymine, cytosine, and guanine) in a DNA molecule. This information is critical for understanding genetic information, mutations, and their roles in disease, evolution, and various biological processes.

-

- Different DNA sequencing approaches using Next Generation sequencing are listed below: -

diff --git a/app/dna-sequencing/components/DNATable.jsx b/app/dna-sequencing/components/DNATable.jsx index e1155ba..25da8db 100644 --- a/app/dna-sequencing/components/DNATable.jsx +++ b/app/dna-sequencing/components/DNATable.jsx @@ -115,17 +115,17 @@ const DNATable = () => { ]; return ( -
-
-

DNA Sequencing Approaches

+
+
+

DNA Sequencing Approaches

Different DNA sequencing approaches and their applications are summarized below:

-
- +
+
diff --git a/app/health/Components/ClinicalAreas.jsx b/app/health/Components/ClinicalAreas.jsx index 0b9ee19..9a52c1a 100644 --- a/app/health/Components/ClinicalAreas.jsx +++ b/app/health/Components/ClinicalAreas.jsx @@ -6,12 +6,12 @@ export default function ClinicalAreas() { return (
{/* Heading */} -

+

Precise Solutions for Clinical Areas

{/* Subtext */} -

+

Empowering you with precise, tailored approaches to diagnostics and care — addressing the unique needs of each clinical area to improve patient outcomes.

diff --git a/app/health/Components/HealthIntro.jsx b/app/health/Components/HealthIntro.jsx index b014870..4c8e909 100644 --- a/app/health/Components/HealthIntro.jsx +++ b/app/health/Components/HealthIntro.jsx @@ -4,46 +4,40 @@ import Link from "next/link"; export default function AboutHealth() { return ( -
- {/* Title */} -

About Health

- - {/* Intro Section */} -
- {/* Left Content */} -
-

- At Operify Health, we believe every patient deserves answers that are not only - accurate — but actionable. By harnessing the power of Next Generation Sequencing - (NGS), we transform patient samples into rich genomic insights that enable - clinicians and oncologists to make informed, personalized decisions. From rare - genetic disorders to complex oncological cases, our solutions help uncover what - traditional diagnostics often miss. -

-

- Our strength lies in our multidisciplinary team of researchers, bioinformaticians, - and data scientists who use custom-built algorithms and cutting-edge analytics to - interpret genetic data with unmatched depth. Backed by curated scientific evidence - and real-world clinical findings, we deliver recommendations that are current, - relevant, and patient-focused. -

-

- With every genome we decode, we move closer to truly personalized medicine — - bridging data and care, science and life. -

-
- - {/* Right Image */} -
- +
+
+
+
+
    +
  • + + At Operify Health, we believe every patient deserves answers that are not only + accurate — but actionable. By harnessing the power of Next Generation Sequencing + (NGS), we transform patient samples into rich genomic insights that enable + clinicians and oncologists to make informed, personalized decisions. From rare + genetic disorders to complex oncological cases, our solutions help uncover what + traditional diagnostics often miss. + +
    • +
  • + + Our strength lies in our multidisciplinary team of researchers, bioinformaticians, + and data scientists who use custom-built algorithms and cutting-edge analytics to + interpret genetic data with unmatched depth. Backed by curated scientific evidence + and real-world clinical findings, we deliver recommendations that are current, + relevant, and patient-focused. + +
    • +
  • + + With every genome we decode, we move closer to truly personalized medicine — + bridging data and care, science and life. + +
    • +
+
-
+ ); } \ No newline at end of file diff --git a/app/health/Components/HealthTitle.jsx b/app/health/Components/HealthTitle.jsx index 74cc12e..85d8334 100644 --- a/app/health/Components/HealthTitle.jsx +++ b/app/health/Components/HealthTitle.jsx @@ -3,7 +3,7 @@ import React from 'react'; const HealthTitle = () => { return (
{/* Breadcrumb */} diff --git a/app/health/components/ClinicalAreas.jsx b/app/health/components/ClinicalAreas.jsx index 0b9ee19..9a52c1a 100644 --- a/app/health/components/ClinicalAreas.jsx +++ b/app/health/components/ClinicalAreas.jsx @@ -6,12 +6,12 @@ export default function ClinicalAreas() { return (
{/* Heading */} -

+

Precise Solutions for Clinical Areas

{/* Subtext */} -

+

Empowering you with precise, tailored approaches to diagnostics and care — addressing the unique needs of each clinical area to improve patient outcomes.

diff --git a/app/health/components/HealthIntro.jsx b/app/health/components/HealthIntro.jsx index b014870..4c8e909 100644 --- a/app/health/components/HealthIntro.jsx +++ b/app/health/components/HealthIntro.jsx @@ -4,46 +4,40 @@ import Link from "next/link"; export default function AboutHealth() { return ( -
- {/* Title */} -

About Health

- - {/* Intro Section */} -
- {/* Left Content */} -
-

- At Operify Health, we believe every patient deserves answers that are not only - accurate — but actionable. By harnessing the power of Next Generation Sequencing - (NGS), we transform patient samples into rich genomic insights that enable - clinicians and oncologists to make informed, personalized decisions. From rare - genetic disorders to complex oncological cases, our solutions help uncover what - traditional diagnostics often miss. -

-

- Our strength lies in our multidisciplinary team of researchers, bioinformaticians, - and data scientists who use custom-built algorithms and cutting-edge analytics to - interpret genetic data with unmatched depth. Backed by curated scientific evidence - and real-world clinical findings, we deliver recommendations that are current, - relevant, and patient-focused. -

-

- With every genome we decode, we move closer to truly personalized medicine — - bridging data and care, science and life. -

-
- - {/* Right Image */} -
- +
+
+
+
+
    +
  • + + At Operify Health, we believe every patient deserves answers that are not only + accurate — but actionable. By harnessing the power of Next Generation Sequencing + (NGS), we transform patient samples into rich genomic insights that enable + clinicians and oncologists to make informed, personalized decisions. From rare + genetic disorders to complex oncological cases, our solutions help uncover what + traditional diagnostics often miss. + +
    • +
  • + + Our strength lies in our multidisciplinary team of researchers, bioinformaticians, + and data scientists who use custom-built algorithms and cutting-edge analytics to + interpret genetic data with unmatched depth. Backed by curated scientific evidence + and real-world clinical findings, we deliver recommendations that are current, + relevant, and patient-focused. + +
    • +
  • + + With every genome we decode, we move closer to truly personalized medicine — + bridging data and care, science and life. + +
    • +
+
-
+
); } \ No newline at end of file diff --git a/app/health/components/HealthTitle.jsx b/app/health/components/HealthTitle.jsx index 74cc12e..85d8334 100644 --- a/app/health/components/HealthTitle.jsx +++ b/app/health/components/HealthTitle.jsx @@ -3,7 +3,7 @@ import React from 'react'; const HealthTitle = () => { return (
{/* Breadcrumb */} diff --git a/app/health/oncology/Components/HereditaryCancerPanel.jsx b/app/health/oncology/Components/HereditaryCancerPanel.jsx index 1f0f1cd..b21a77c 100644 --- a/app/health/oncology/Components/HereditaryCancerPanel.jsx +++ b/app/health/oncology/Components/HereditaryCancerPanel.jsx @@ -9,29 +9,32 @@ export default function HereditaryCancerPanel() { { title: "Genetic Counseling Support", desc: "Optional access to pre- and post-test counseling for patient education and informed decision-making." } ]; + const points = [ + "About 5-10% of all cancers are linked to inherited genetic mutations, often going undetected until late stages or after multiple family members are affected.", + "The Operify Hereditary Cancer Panel screens key high- and moderate-risk genes associated with hereditary cancer syndromes like HBOC, Lynch Syndrome (LS), Li Fraumeni Syndrome (LFS), Familial Adenomatous Polyposis (FAP), Cowden Syndrome (CS), Peutz-Jeghers Syndrome (PJS), Neurofibromatosis (NF) etc.", + "Early identification of germline mutations enables proactive clinical decisions, including risk-reducing strategies, targeted surveillance, and family cascade testing.", + "Studies show that genetic testing in hereditary cancer cases improves outcomes and informs care for both patients and at-risk relatives." + ]; + return ( -
-

Operify Hereditary Cancer Panel

+
+

Operify Hereditary Cancer Panel

-

- About 5-10% of all cancers are linked to inherited genetic mutations, often going - undetected until late stages or after multiple family members are affected. -

-

- The Operify Hereditary Cancer Panel screens key high- and moderate-risk genes associated - with hereditary cancer syndromes like HBOC, Lynch Syndrome (LS), Li Fraumeni Syndrome (LFS), - Familial Adenomatous Polyposis (FAP), Cowden Syndrome (CS), Peutz-Jeghers Syndrome (PJS), - Neurofibromatosis (NF) etc. -

-

- Early identification of germline mutations enables proactive clinical decisions, including - risk-reducing strategies, targeted surveillance, and family cascade testing. -

-

- Studies show that genetic testing in hereditary cancer cases improves outcomes and informs - care for both patients and at-risk relatives. -

+
    + {points.map((point, idx) => ( +
  • + +

    + {idx === 0 ? "About 5-10% of all cancers are linked to inherited genetic mutations" : ""} + {idx === 0 ? ", often going undetected until late stages or after multiple family members are affected." : point} +

    +
    • + ))} +

Key Features

@@ -45,7 +48,7 @@ export default function HereditaryCancerPanel() {
{features.map((feature, idx) => ( - + diff --git a/app/health/oncology/Components/OncologyIntro.jsx b/app/health/oncology/Components/OncologyIntro.jsx index 448bda3..7d1b1a3 100644 --- a/app/health/oncology/Components/OncologyIntro.jsx +++ b/app/health/oncology/Components/OncologyIntro.jsx @@ -1,31 +1,52 @@ export default function OncologyIntro() { return ( -
-

Oncology

-

Turning Complexity into Clarity

-

- Cancer is not a single disease—it's a highly complex and dynamic group of disorders, - often driven by a multitude of genomic alterations. Despite advancements in treatment, - many patients still face uncertainty due to incomplete or delayed molecular diagnoses. -

-

- At Operify Health, we recognize that behind every tumor is a unique genetic story waiting - to be told. Our precision oncology solutions utilize high-throughput Next Generation - Sequencing (NGS) to analyze both somatic and germline mutations—providing clinicians - with actionable insights that inform targeted therapies, immunotherapy decisions, and - hereditary cancer risk assessments. -

-

- This genomic-driven approach is especially critical in advanced and treatment-resistant - cancers, where conventional methods often fall short. Studies have shown that integrating - broad-panel NGS into cancer care can impact clinical decision-making in up to 30% of cases, - leading to more personalized and effective treatment strategies. -

-

- By combining cutting-edge sequencing, advanced bioinformatics, and curated clinical evidence, - Operify Health empowers oncologists to move from uncertainty to precision—ensuring every cancer - patient's care is as individualized as their diagnosis. -

+
+
+
+
+

+ Turning Complexity into Clarity +

+
    +
  • +
    + + Cancer is not a single disease—it's a highly complex and dynamic group of disorders, + often driven by a multitude of genomic alterations. Despite advancements in treatment, + many patients still face uncertainty due to incomplete or delayed molecular diagnoses. + +
    • +
  • +
    + + At Operify Health, we recognize that behind every tumor is a unique genetic story waiting + to be told. Our precision oncology solutions utilize high-throughput Next Generation + Sequencing (NGS) to analyze both somatic and germline mutations—providing clinicians + with actionable insights that inform targeted therapies, immunotherapy decisions, and + hereditary cancer risk assessments. + +
    • +
  • +
    + + This genomic-driven approach is especially critical in advanced and treatment-resistant + cancers, where conventional methods often fall short. Studies have shown that integrating + broad-panel NGS into cancer care can impact clinical decision-making in up to 30% of cases, + leading to more personalized and effective treatment strategies. + +
    • +
  • +
    + + By combining cutting-edge sequencing, advanced bioinformatics, and curated clinical evidence, + Operify Health empowers oncologists to move from uncertainty to precision—ensuring every cancer + patient's care is as individualized as their diagnosis. + +
    • +
+
+
+
); } \ No newline at end of file diff --git a/app/health/oncology/components/HereditaryCancerPanel.jsx b/app/health/oncology/components/HereditaryCancerPanel.jsx index 1f0f1cd..b21a77c 100644 --- a/app/health/oncology/components/HereditaryCancerPanel.jsx +++ b/app/health/oncology/components/HereditaryCancerPanel.jsx @@ -9,29 +9,32 @@ export default function HereditaryCancerPanel() { { title: "Genetic Counseling Support", desc: "Optional access to pre- and post-test counseling for patient education and informed decision-making." } ]; + const points = [ + "About 5-10% of all cancers are linked to inherited genetic mutations, often going undetected until late stages or after multiple family members are affected.", + "The Operify Hereditary Cancer Panel screens key high- and moderate-risk genes associated with hereditary cancer syndromes like HBOC, Lynch Syndrome (LS), Li Fraumeni Syndrome (LFS), Familial Adenomatous Polyposis (FAP), Cowden Syndrome (CS), Peutz-Jeghers Syndrome (PJS), Neurofibromatosis (NF) etc.", + "Early identification of germline mutations enables proactive clinical decisions, including risk-reducing strategies, targeted surveillance, and family cascade testing.", + "Studies show that genetic testing in hereditary cancer cases improves outcomes and informs care for both patients and at-risk relatives." + ]; + return ( -
-

Operify Hereditary Cancer Panel

+
+

Operify Hereditary Cancer Panel

-

- About 5-10% of all cancers are linked to inherited genetic mutations, often going - undetected until late stages or after multiple family members are affected. -

-

- The Operify Hereditary Cancer Panel screens key high- and moderate-risk genes associated - with hereditary cancer syndromes like HBOC, Lynch Syndrome (LS), Li Fraumeni Syndrome (LFS), - Familial Adenomatous Polyposis (FAP), Cowden Syndrome (CS), Peutz-Jeghers Syndrome (PJS), - Neurofibromatosis (NF) etc. -

-

- Early identification of germline mutations enables proactive clinical decisions, including - risk-reducing strategies, targeted surveillance, and family cascade testing. -

-

- Studies show that genetic testing in hereditary cancer cases improves outcomes and informs - care for both patients and at-risk relatives. -

+
    + {points.map((point, idx) => ( +
  • + +

    + {idx === 0 ? "About 5-10% of all cancers are linked to inherited genetic mutations" : ""} + {idx === 0 ? ", often going undetected until late stages or after multiple family members are affected." : point} +

    +
    • + ))} +

Key Features

@@ -45,7 +48,7 @@ export default function HereditaryCancerPanel() {
{features.map((feature, idx) => ( - + diff --git a/app/health/oncology/components/OncologyIntro.jsx b/app/health/oncology/components/OncologyIntro.jsx index 448bda3..7d1b1a3 100644 --- a/app/health/oncology/components/OncologyIntro.jsx +++ b/app/health/oncology/components/OncologyIntro.jsx @@ -1,31 +1,52 @@ export default function OncologyIntro() { return ( -
-

Oncology

-

Turning Complexity into Clarity

-

- Cancer is not a single disease—it's a highly complex and dynamic group of disorders, - often driven by a multitude of genomic alterations. Despite advancements in treatment, - many patients still face uncertainty due to incomplete or delayed molecular diagnoses. -

-

- At Operify Health, we recognize that behind every tumor is a unique genetic story waiting - to be told. Our precision oncology solutions utilize high-throughput Next Generation - Sequencing (NGS) to analyze both somatic and germline mutations—providing clinicians - with actionable insights that inform targeted therapies, immunotherapy decisions, and - hereditary cancer risk assessments. -

-

- This genomic-driven approach is especially critical in advanced and treatment-resistant - cancers, where conventional methods often fall short. Studies have shown that integrating - broad-panel NGS into cancer care can impact clinical decision-making in up to 30% of cases, - leading to more personalized and effective treatment strategies. -

-

- By combining cutting-edge sequencing, advanced bioinformatics, and curated clinical evidence, - Operify Health empowers oncologists to move from uncertainty to precision—ensuring every cancer - patient's care is as individualized as their diagnosis. -

+
+
+
+
+

+ Turning Complexity into Clarity +

+
    +
  • +
    + + Cancer is not a single disease—it's a highly complex and dynamic group of disorders, + often driven by a multitude of genomic alterations. Despite advancements in treatment, + many patients still face uncertainty due to incomplete or delayed molecular diagnoses. + +
    • +
  • +
    + + At Operify Health, we recognize that behind every tumor is a unique genetic story waiting + to be told. Our precision oncology solutions utilize high-throughput Next Generation + Sequencing (NGS) to analyze both somatic and germline mutations—providing clinicians + with actionable insights that inform targeted therapies, immunotherapy decisions, and + hereditary cancer risk assessments. + +
    • +
  • +
    + + This genomic-driven approach is especially critical in advanced and treatment-resistant + cancers, where conventional methods often fall short. Studies have shown that integrating + broad-panel NGS into cancer care can impact clinical decision-making in up to 30% of cases, + leading to more personalized and effective treatment strategies. + +
    • +
  • +
    + + By combining cutting-edge sequencing, advanced bioinformatics, and curated clinical evidence, + Operify Health empowers oncologists to move from uncertainty to precision—ensuring every cancer + patient's care is as individualized as their diagnosis. + +
    • +
+
+
+
); } \ No newline at end of file diff --git a/app/health/rare-disorders/components/ClinicalAreasGrid.jsx b/app/health/rare-disorders/components/ClinicalAreasGrid.jsx index 0752080..a9d1449 100644 --- a/app/health/rare-disorders/components/ClinicalAreasGrid.jsx +++ b/app/health/rare-disorders/components/ClinicalAreasGrid.jsx @@ -21,8 +21,8 @@ export default function ClinicalAreasGrid() { ]; return ( -
-

Clinical Areas

+
+

Clinical Areas

{areas.map((area, idx) => (
-

Operify Exome

+
+

Operify Exome

-

- Whole Exome Sequencing (WES) targets the protein-coding regions of the genome, where most - disease-causing mutations are found. -

-

- With over 7,000 rare diseases identified—80% of which have a genetic basis—WES offers a - powerful approach to uncover their causes. -

-

- Traditional diagnostic methods can be slow, costly, and inconclusive; WES streamlines the - process by delivering broad genetic insights in a single test. -

-

- Operify Exome enhances WES by combining comprehensive coverage with advanced interpretation, - improving diagnostic yield and patient outcomes. -

+
    + {points.map((point, idx) => ( +
  • + +

    + {point} +

    +
    • + ))} +
-

Key Features

+

Key Features

@@ -146,7 +146,7 @@ const DNATable = () => { {sequencingData.map((row, index) => (
- + {row.approach.name}
{feature.title} {feature.desc}
{feature.title} {feature.desc}
diff --git a/app/health/rare-disorders/components/OperifyExomeMito.jsx b/app/health/rare-disorders/components/OperifyExomeMito.jsx index 08f42a7..c941f53 100644 --- a/app/health/rare-disorders/components/OperifyExomeMito.jsx +++ b/app/health/rare-disorders/components/OperifyExomeMito.jsx @@ -14,52 +14,48 @@ export default function OperifyExomeMito() { { genome: "Mitochondrial genome", coverage: "37 genes" } ]; + const points = [ + "The Operify ExomeMito Panel offers a unified solution by integrating whole exome sequencing with complete mitochondrial genome analysis—addressing both nuclear and mitochondrial causes of disease.", + "This combined approach is especially valuable in diagnosing complex, multisystemic, and rare disorders, where variants may exist across both genomes.", + "Mitochondrial disorders, though individually rare, are clinically significant, affecting approximately 1 in 5,000 individuals and often missed in standard testing.", + "Studies show that adding mitochondrial sequencing to exome testing increases diagnostic yield by up to 20%, offering greater clarity and clinical confidence. (PMID: 30369941)", + "While screening for rare genetic disorders, it's essential not to overlook the rarest among them-mitochondrial disorders, which occur in approximately 1 in 5,000 individuals. Although individually rare, their cumulative impact is significant in the context of rare disease diagnostics. Multiple studies have demonstrated a substantial increase in diagnostic yield—up to 20%—when mitochondrial genome sequencing is performed alongside whole exome sequencing. Reference: PMID: 30369941" + ]; + return ( -
-

Operify ExomeMito

+
+

Operify ExomeMito

Boost diagnostic yield with Exome + Mito Sequencing

-
-

- The Operify ExomeMito Panel offers a unified solution by integrating whole exome sequencing - with complete mitochondrial genome analysis—addressing both nuclear and mitochondrial causes - of disease. -

-

- This combined approach is especially valuable in diagnosing complex, multisystemic, and rare - disorders, where variants may exist across both genomes. -

-

- Mitochondrial disorders, though individually rare, are clinically significant, affecting - approximately 1 in 5,000 individuals and often missed in standard testing. -

-

- Studies show that adding mitochondrial sequencing to exome testing increases diagnostic - yield by up to 20%, offering greater clarity and clinical confidence. (PMID: 30369941) -

-

- While screening for rare genetic disorders, it's essential not to overlook the rarest among - them-mitochondrial disorders, which occur in approximately 1 in 5,000 individuals. Although - individually rare, their cumulative impact is significant in the context of rare disease - diagnostics. Multiple studies have demonstrated a substantial increase in diagnostic yield—up - to 20%—when mitochondrial genome sequencing is performed alongside whole exome sequencing. - Reference: PMID: 30369941 -

+
+
    + {points.map((point, idx) => ( +
  • + +

    + {point} +

    +
    • + ))} +
-

Genome Coverage

+

Genome Coverage

- - - + + + {genomeCoverage.map((item, idx) => ( - + @@ -69,18 +65,18 @@ export default function OperifyExomeMito() { -

Key Features

+

Key Features

GenomeCoverage
GenomeCoverage
{item.genome} {item.coverage}
- - - + + + {features.map((feature, idx) => ( - + diff --git a/app/health/rare-disorders/components/RareIntro.jsx b/app/health/rare-disorders/components/RareIntro.jsx index 2e2cf9f..efcaeda 100644 --- a/app/health/rare-disorders/components/RareIntro.jsx +++ b/app/health/rare-disorders/components/RareIntro.jsx @@ -1,18 +1,33 @@ export default function RareIntro() { return ( -
-

Rare Disorders

-

Transforming Delays into Diagnoses

-

- There are over 7,000 identified rare diseases, many of which begin in childhood—and - nearly 80% have a genetic cause. Yet, the average time to diagnose a rare disorder is - still 4.8 years, with some cases taking up to 20 years. -

-

- At Operify Health, we leverage advanced Next Generation Sequencing (NGS) and proprietary - bioinformatics to deliver rapid, reliable insights—helping reduce the diagnostic journey - from years to days. -

+
+
+
+
+

+ Transforming Delays into Diagnoses +

+
    +
  • +
    + + There are over 7,000 identified rare diseases, many of which begin in childhood—and + nearly 80% have a genetic cause. Yet, the average time to diagnose a rare disorder is + still 4.8 years, with some cases taking up to 20 years. + +
    • +
  • +
    + + At Operify Health, we leverage advanced Next Generation Sequencing (NGS) and proprietary + bioinformatics to deliver rapid, reliable insights—helping reduce the diagnostic journey + from years to days. + +
    • +
+
+
+
); } \ No newline at end of file diff --git a/app/health/rare-disorders/components/SampleRequirements.jsx b/app/health/rare-disorders/components/SampleRequirements.jsx index 5045f1e..5dc3bf9 100644 --- a/app/health/rare-disorders/components/SampleRequirements.jsx +++ b/app/health/rare-disorders/components/SampleRequirements.jsx @@ -1,36 +1,49 @@ -export default function SampleRequirements({ title, items }) { - return ( -
-
-

{title} Sample Requirements

- -
- {/* Turnaround Time */} -
-
- - - -
-
-

Turnaround Time

-

21 Days

-
-
+import Image from "next/image"; - {/* Sample Requirement */} -
-
- - - -
-
-

Sample Requirement

-

Blood/Saliva/Cheek Swab/Genomic DNA/Dry Blood Spot

+export default function SampleRequirements({ title, items }) { + const requirements = [ + { + icon: "/images/icons/clock.png", // Replace with your actual icon path + title: "Turnaround Time", + description: "21 Days" + }, + { + icon: "/images/icons/sample.png", // Replace with your actual icon path + title: "Sample Requirement", + description: "Blood/Saliva/Cheek Swab/Genomic DNA/Dry Blood Spot" + } + ]; + + return ( +
+

{title} Sample Requirements

+ +
+ {requirements.map((req, idx) => ( +
+
+
+ +
+
+

{req.title}

+

+ {req.description} +

+
-
+ ))}
); diff --git a/app/health/rare-disorders/components/SolutionsOffer.jsx b/app/health/rare-disorders/components/SolutionsOffer.jsx index 7ebfb26..f59ad2b 100644 --- a/app/health/rare-disorders/components/SolutionsOffer.jsx +++ b/app/health/rare-disorders/components/SolutionsOffer.jsx @@ -11,19 +11,30 @@ export default function SolutionsOffer() { ]; return ( -
-

Our Rare Disease Solutions Offer

-
+
+

Our Rare Disease Solutions Offer

+ +

+ Comprehensive genomic sequencing solutions designed to unlock genetic insights + and accelerate diagnosis for rare disease patients and their families. +

+ +
{solutions.map((sol, idx) => (
-

{sol.name}

-

{sol.desc}

+
+
+

{sol.name}

+

{sol.desc}

+
+
))}
-
+ ); } \ No newline at end of file diff --git a/app/health/rare-disorders/components/WESInfo.jsx b/app/health/rare-disorders/components/WESInfo.jsx index d9c038a..335ea25 100644 --- a/app/health/rare-disorders/components/WESInfo.jsx +++ b/app/health/rare-disorders/components/WESInfo.jsx @@ -1,22 +1,28 @@ export default function WESInfo() { + const points = [ + "Whole Exome Sequencing (WES) is recommended for individuals with unexplained genetic disorders, complex or atypical clinical presentations, or when prior genetic tests have been inconclusive.", + "It is especially valuable in diagnosing rare inherited diseases, uncovering the cause of developmental delays, intellectual disabilities, or early-onset neurological conditions, and providing insights for personalized treatment planning.", + "WES can help identify genetic causes in a wide range of rare disorders." + ]; + return ( -
-

+
+

Who Should Consider Whole Exome Sequencing (WES)?

-

- Whole Exome Sequencing (WES) is recommended for individuals with unexplained genetic - disorders, complex or atypical clinical presentations, or when prior genetic tests - have been inconclusive. -

-

- It is especially valuable in diagnosing rare inherited diseases, uncovering the cause - of developmental delays, intellectual disabilities, or early-onset neurological - conditions, and providing insights for personalized treatment planning. -

-

- WES can help identify genetic causes in a wide range of rare disorders. -

+
    + {points.map((point, idx) => ( +
  • + +

    + {point} +

    +
    • + ))} +
); } \ No newline at end of file diff --git a/app/rna-sequencing/components/AboutRNA.jsx b/app/rna-sequencing/components/AboutRNA.jsx index f67eda8..5afd5c6 100644 --- a/app/rna-sequencing/components/AboutRNA.jsx +++ b/app/rna-sequencing/components/AboutRNA.jsx @@ -4,8 +4,8 @@ import React from 'react'; const AboutRNA = () => { return (
-
-

+
+

About RNA Sequencing

@@ -16,9 +16,6 @@ const AboutRNA = () => {

RNA sequencing (RNA-Seq) is a method used to determine the sequence and quantity of RNA present in a sample, providing insight into gene expression, alternative splicing, and non-coding RNA functions. It is essential for understanding various biological processes, including disease mechanisms, gene regulation, and cellular responses.

-

- Different RNA sequencing approaches using Next-Generation Sequencing (NGS) are listed below: -

diff --git a/app/rna-sequencing/components/RNATable.jsx b/app/rna-sequencing/components/RNATable.jsx index 003d3ef..15fd452 100644 --- a/app/rna-sequencing/components/RNATable.jsx +++ b/app/rna-sequencing/components/RNATable.jsx @@ -106,7 +106,7 @@ const RNATable = () => { return (
-
+

RNA Sequencing Approaches

FeatureDescription
FeatureDescription
{feature.title} {feature.desc}
@@ -130,7 +130,7 @@ const RNATable = () => { {sequencingData.map((row, index) => ( diff --git a/public/images/icons/clock.png b/public/images/icons/clock.png new file mode 100644 index 0000000000000000000000000000000000000000..6829e392a36432643eb6d7f95b642b5ea31c267c GIT binary patch literal 10492 zcmXY1Wmp?sw;kM}6e#W2LM3td3!<)<}2s`5J~!^TE2w-LdFt%VL%sT!3FVfzam4i5Dlq023r?Sd1-_rWg@ zSA6G$sHue<5Q+@qrQu?V55*SK3`k_2pt;R-7-#pU(v?a*;on=?dG-=GlbT-H`-#jy zzPKhFRDi^d@}dhHGz;% zT{iiEr4Uf2zRf}Ip{bgQEAdi1gc6C>j?KLpR_7U~7n_LSzV)iCT_8CHr_nP#N1vH> zgRVSFA565_nS+cl@j7mUl+=Li$iqDh_spKdh$8x`lQ#PN1y-(+(-N;9DjrXFft&TL z$GmegloL#ZP6XYEl*Fl338RpEf%je@J4axHzumZLgj}}yqb2(?@P2N2sj(xDnS=!- zK}iH73pXV-j}yazjPZHMFL)&j{USQF{vErn4p;GA>gDM~Oq|axl&ws2 z0W4gRGm?GK-<3_%7WpwN=evB)+|BN2%$>tcQIsJ>s>VnyTYG@CC&@%a}(qb3cs=Z)6sC z;|m#0U8_V3_`^jGjTUFPG|H?w*hV`FCvaEk3GZ(Ty8S+PQ(iiofV@>KS%zQeY? z+d&20I_WlPqO543rjyEkKX{Os>W#-*2E>K-Hnxul1vdQMknF6ct~I`ZKyHP39`n|x zO@asChJ37n<(zV5K0#H754lNGg2!_pQViq^Ij&_-^{Ie(wq*c5$AM7S`}PcV!?LqW zYThVf_)8AudPT-;+s6YD=@@H3d%F6-H|_0={77--zhC=CC-uj*B?$Wl;+Pn>d&9iPuSM{ zbRsHkX2RWZuyHu$lEQu8P+|diT3-ioM?PUEXF4*e9VlJhDBd0W7i5~nR!}pmP6Ahf z2Xz4%b6%S9G62hg8^wm70LlgGSvZI#IFA9xOchxd=Y0jTROM7W>D=dLct9Q5{$lDH zaC^k$g}Dl-j=SUd`|i{~kAmPdcR&x?o&K0SfK;>_(sR{o+?yA*zRH>o0 zZ>TL0a1)q^x$D!;aiE2|05HNN0#PA>QE6sEE8FF$ocKWf6mEP&FH-Xy z;+B|g1D1y=Nsi=SCg-M=y$*|O-Zdq^!1E>VAPU+&4_?+kKPtzdW!nn(7#9`^B1FnJ zCn~u?Z^{=Ib;!(qAdOch)y{Afrm;#EwC+%u6x1Wy(@(7%iZnMdC?+ zpjAKPuDz=LRk#GEh;$M`)LyLnIB}dCQ~`zknSC$&3HPiZ-xA*k4ceu2C`0V30%^3V zgH~6O=)yX}*5T`e@a);AXd}9)`6>q0t2hoh{>wOKShDpwMcT-h#7P#E*U-;nAsjW$ zB!0*iKy#x_Y=?jov7Pu-9crF>yjTupxt^9y(sVN?m9Ao}qv4iKyZ#fnQ&!AWacLYw zMYZGKN%gdPtWJWYHhasXIf=i!0wMkWnJ>g&Pp$-mL1H=G-&AaG zrrJnlp0-`E5$<0!KWavZRbz9B1?~?B}?9o+^_@ zJ*$rih1zSp5{pJ)oMoF6t&#X}yRQv5o<^8eSU=y_7b{ckr2iU{fW47z&a_5q1zX6h z9HCz^6}gux%Q6`~HOTcwpPiU21GU#zD&%#41;y^(|8io;13i8IWp54Qz8m}MZJ~d7 zm3eT`om$5(cJH#0oPV?!7`2bvT98TFn^;xza#X_BFUqLYt|pBz7HobL&xJE}S_#Vo zfn~j-&`wfnEUAr0=eLxd@k(#noTrv<#!ji`Os1!ya?g`8?p-YG&ukb5C72+LcwHEc z4zijCZDaC@Xh$ZPx#Ej;k}-~{mFsU)y()g~aA$5|659w& zVm%~w;e6U;|Gan2DI*Z_^4h|DALs%+QtP4&x#3h?+jX!kN~lrm%5xlg6EN#T@n=oB zx>vQ*eWo00f(?k21vkwX^j4b#Uhcb8I7^Z*hWb#mKbebpZo>5mI7hPT^_%zg0|$7h z_zHwJsgZa_(=r~FvCmP6@$)XRhH{~{dD+c^?Xd>Y4^%f2JEgpTr}qV^$9XKz&`0Jo zLqai9(nT}YVbD~K`-c>C9VfKx3B6a_;3t17-j*|3q-%5NpsM9^`4w!k0yp>yGF16v7;X=KbKG_r)CpcrBaIQdKlea{`0b@J9Lv# z%)gOOVTZRu=mfhGS!&y19E+!s8ptx>^~tlBcWvZ8Jn+am+a?a`Q5-_OoM4}yPxF`# za=DDMxI7YC_LYB9xR{sR+=g7#b%b9v9%8)Fo2ImvJVQpv!%OO^%-y&2;AmTgw|o3o z;Eu8N)!K$ufA(X^SpVp!!~V)4m+ZPj-TEuq*(|ancZ#Oasoc@;>CvZ&wP1BrX%F3c z^q9nGtek2JfW$G;21(lU(L)AboedLrW_f$22JVoq^D|%Nb2LCmD-oyF>eNGY4Ce1o z9FXjd?gz+*7ya-%q7CZ%(Lu4Vek&X|s35$Or`vqX^HnR50Il!yltEeS9*5JbO8hOf zx8L7COv@Dv${^>?67$qFsIviv35XV!hIaYXa9Fxf`^Z(Uz$eesbwmt7Q` z+c(LiueEgzH7}ib_E4-Gz#CwHq@(}U7?q&fgKu@88d*V!*{d$`t>t@&Wq2Ujh+@rO z=J;hF#+*tt{NC*MC-4ig`?tl~E%Kx@e`%6MGwLs?ZgY)sp@rZz+%L^}PfzHA;p7Te zkO+{%6XaTdbm%Om5L1xpnz^E-Dj~1eyjEU*4~S45JzI-iPv1vAM2Tk5OuzUsyJtV{vK5mvJ(AZd}sS^6NUJWinQcMCI2DPLyhS6!K2Kf*qUeN^nv6P}oas5~2G^dBJTd?FG4oOX{9#Uuig5Jeg&2)-lQ= zKgAs4D9I79tpSdc+XO^56ifJCy^1@smBqA?E;Wf9`AaD>S=c5YCdY`A_cvCG$_okg ziI-hr=&oLdO*#z=wru2>%dE#%KUkv=6TIy_1b+pI^xgeV&!Ia-!#qe`$LSP`h#6%z zS6X8CElTw-JSTvEspU;+XrX<^gl`FaMvx#fV}7^!7t=nf8)LUL7EjGf;gE(5_% zcXeMBlMz~{VD5{@hKBNaJ@r|-%-NLgOhNmLG{^+u-5ECZd;Lni4P|tVHEtCjG@>1edp_F3oxxBnwW)7X zvutcp;OQbSR_D_A7W^2;bY+I5&8@{B9N_kw5d z!ts|m`I#pCZxMq?8RqPEqUPP&x8__Zu4XwIFJdLDVQK&6^hY#1WyoMuA`Ib%R0gk$ z`W?pYRDfDDlzuQ>y$SUY8Zs^nHES}Hig^(0C%~JFpSQWD!(&q5x&f3>%jm8e5Efej zvwfawb!!j4`Yup#E35EWIYoTS~?H=~0`lE;pRdQ`!Jt61#W- zd6Y%Pm3Z9Lf&S1#wb4ENa>Xa^WYIGkJt2X|~|#k92A8D$W}dIXc&M$KeX7bS0)#G*qT% zR+~?5C1wB!N5kK_^u_$(RK7aV6RPI=V+to8Tqh=#CAeUV`d_&gpH0f4k5%aoB^XRr zVFE=sUlQ#XTR~}<4WrlK9;q_ARSrWa4i zaY4i{$U@xxR#E^qU%Dklu%%{NaG*Q2?w4*G`?ThchBnd#8<>g6W`1m*St~i<0mb~( zZPG($xEgrpb#U6cRYm*ngcA(x86~g(l}R`Y3N+H1BP`;c{TZv|b<8~I=}0BBZ+kn~ zPC?44J}V@%UzW%xVe%7{A0+4MG4WO*jeE*(zvV-b^hRQAeo0oTZ~^Ve|= zv?T!BG#RnoNwICwRd$$w-1a6m-Fb%i!14iER8U-p0f<<~DzPuMxC>iaej?5ltQFozFN3p7bO2;f17-gwWJQU2phy)-wfF z_Z|~Px(k76DUmC*%V?%y={18}VN*hI^_qjSbClpPNLZT#yf)YO?9-4UOV(|>U0Z=h zW2BX6(x-;jDTN!wl_8{hJOH^*Nt*-kF_NXF%XLYKG}lbTU*>~(H;uLt^2WRf->#6S z5rCO1(qLy&P%8!~;?5a|*({Y|5IMQ0Kek@jN?*CqY-uK%%AzC}7i(z(m^ZnSQmj2*^lM+I+C_J)?nYEsKRF3ET)mxN;Rx=&S^qztK9YrPE;) z7pi)+Sz8}$lbHp+v1OWQ?q07$b8ljb=Yfta?PVgyb?X_2%Y4j$zJITzq~mO2i6*^0 z_;>R;;(4JpGvE1!t0^X5-@QZsNT7Pnng^L^=%2oMus9+3o!TMWNTRAzx(^S~l7dQr zJ*|)yZlN=y*r)u8!zafgCdA3rTUvS3))9*P1PlQ6>opw2lk?R+2yatRQ3O z{td2fnG7CU5AUmCWMGT@TpczDK0NasbWJo7>nD%bm4nB2O!(g!=FE2(MU!9uJ5l<$ z1P~Fq!x?CrbPF#G8Vk)%a00_1Ec7ARIH;alqa>)BGPcd&jTBToc;T!;*SY>4x!5!M7Q{BZ)}48N^;lM01q^in=b0oaUC z2pWQu2r*bR1N~*-n<<8uW!Z60E*tK2R|j+Vf|@T;=NbMZPmenGoFY8>3t{lf$m`cX z=jHyQ696(q{xS$-f9iOzs&9?k`x-~PYDEoaq{!2;bzt!w)kHQ;zPZJ$Br(HhRk|Lg!efJ zJ~9&M8vHp->P#UGV6dp>zd6?LBAQSig?9{>XQ_YBa|yGu%{1ys-RGeOO(Y!73I6!0 zrC+E{=I;o`Qx>7D!1C!oje8=FcK@VB>b??95z42RaWtAN^Cag=^hg4|E(tUiR<&}- z6X@;wfvOLMcx=L^$5D;YfrES50Ca1I_m#5UY&87c=B5}=K{IzN{e5VN;l*GhuXNY4 z7+sxJpP9)jWyfH1pZ1DhxzVR^@z)ed%?%2;amv*p{T zogv%tR+&v+#D6PeQ8?hNM&V7uFC4xRD85fU#y>!tm^53eAl`v~0w&cz{|0n&yZL*F zo+dh$=J$}zZ8dY49JUPvH-O-S;cG=J7(DT>J?^W&nxYomUoLiBOkZR+Tf)C_u=wy} zo-#Sg^II&hI{+d(Qhpr1ie{hm0)8hw&uKu&yBSOt;dD@dRMB(+3Sk35iQt6T)%p2{ zhKQb%G;r7Au$LucZH*W0M(B^g#qrzgYNn3Kb>M4pe;>Z9HWu=jJ_ajM&GFl9Wzaiu z2H$csG7HO7;nwH2fE# zZ)*YMZp%{R*(F10)!|OpamqTIuu3EsL6qI!zDh2AC_0Q(S!hYt9TFpM)5R(?uVK7R z-9XCrs`D^8G&0>XPwbD)50-THkR7|zoq5ls>^RBmEL6-zpuBSc8ND6u`_C#|!;nGI zPWr&D1U~oO23gS61MO6YPZTTt>?5aF+ligXbOTh-b)5q5fZa%}N#T`NK?t5;NMJEG zhSgKA8k*237eIuxX7<^X{tb6XlX0Vcanw^YHKtoE4Hkfy)cS3oLO8oV&IP!h?+wLTF@USOQZEmb@BkS z@IGbYcBrd3URfFvN$-OD!i$%FRj5#%BKm+Gty`zwLfYqFp2n^5g#Sii$0b01BbDS7^p{X5!3v~AVH zibWYI&Obewd0(1d>sT)4nCYYFY54i>+@OPXdnlKp7GJW}iEZatT9ZNX%bYmgn!s5N zU>7h9n@OsGiuru%kHP%BY|z1F3=s+l!IR5CfM@7IA;UN0>};hI4`WE+#41@*aTym{Yum?_cqoYBiI>W6p7e3OlBS644UF>j-USH}g^K9yq(8 z6MQJWY9`jMcOh(A9fcFUpQXb>mzlWTT_zavS_i*nRwL(&c>cR`@}|)y!A9&T;2!QB z>gCor$gLo0^tm+M$#(t5%dX`p{GhvU)kDw&y$Ii=t*2>ncvrxX+w}P9W<&~<-1xo< zp@ZWap;qDPRzXHo;Qnu42eR*IRquaE5I@&7Ov^V6yPpzQNCA`@-zWYJ)G`?NYhTqH z!q9r2b#CWXtL+zcc%?f)LEB4g_)l8OH^t>F-GYUm8A#cOYwL;e%dzrYrE#y}c z@(l@vKzzom22Zj~6j^hS`ck$(B5gz?#>Ga`!N|QgHn$^6hzBb z+1|t4_EPq_@)mu^<;-Rzwq|)MAmbmm@Z#5%o1Jl}xX0<_%~J8eXh}!8Wc8o*BCX-G z*^A`UPKHRUV5P}c;e-CG;LVa5+N4sw!8O6f)I(Cuyb8T<`DLjHxsg{D$V&drqpq4|L`}XrH8mv=QRe) zjIG4i5R1O7)DQKFt#U;prW z2O%rf^{fT%HZCTI;u9UI%mrELi(DN!xoYp~%f50Hz)yJNki}RBZx-p5mMgDeL#SN! zL&VSTl`WT%T=%8(UQn)SU2YHbkB{cJEka@=c(sgxH9tR2zB&<{TRO#Ku2yL`L#O>X z19L1yg(r5Aqa;D*OU`b4fyo&-DF|H*42&Epdvj}Y?-FrPApXLVe%mRZ$}90E)0Za= zl6^*yK7occ=);x;@Fu9~<|eQ9c+{w`km=GgMYUrqL71hAt>xBBvE!Z0#sa37G0d4J zOInLScQq&eYbW96w?O?ot1@Sn#xB0ub1u+u=<)+xN}KY**=_jK20}98Q{}o6>9ETE z4=!-3W)m%#P7MuOC_e6aOjfLn%1RaEO|@aFM&!0bCB+qM-)rCybuwuSiOFeT?yVHg zCp7U`&(eP#L)_9%RC;-saq67;;U7IQNmzTGj8tGj5FP_hw)l&MQpbW~?p^E0_?v4K zHg}2Sp6YNq$2on(bk;R)X!m=Yb=p4t$%$~e_8&>xyS}MwY93fV{Hqk!OP_ngKtU!E zN$YyvjG%R{4Mt>zog5!jk_*C) zXz;@t(DJ5jElqba74IqrlWns->L+YSk+pt_X&1KAC!pJ6Elk^e=UVS?4>Yp*=JC>o zi`@>#XZZP4&A;@5_?n$^)KHT$zr3&z+5A>L{9n#`boxi)#VXe=v^U`n@t%7lEwU{j zo~(m$#MVQ?pNG*>6#1aAgL0r)sh1_NnXP0YrmS;obnIEmV1OwEEv3kC!5kO6E*9I- zR37uwkT7psUGLzy7!F@Gb>ozbLlXNgQ;oQ|K_&LZs%f7u3Ns#g|wY(S6$c!JvcA0Xsvv5fQcr+eK-=y>9?lNUc+0mSTFPk4d@(pUI#A1 ziY@^suOZ$12GZXSs7;J0IQ%rt8)fS04q_7n_V2#H0Cs+<3ec-DwC{fg=}W#UL3Hp? zz9iLI_{6HH(|YAQN4a|UpT_41f2M%^ovyXq@9b5eKu2W{B=3ftHs-YCDV|FA-$cZwnpVQyPK{#ku3cgMfBa+{)Abw*2_?K1br;9dWl=p)>3 znkc|GD*&h)ZCd`+Ox@c+j=&>)=p&-NJK%busro%-&;XeQPMBL;D^ZLm%aq}_ZSM|T zkcX~;Fi{iijcDUMGrNsg{;ENlfRcIYLiP4fKh_`|cbMoz?XZLF8&nn2NLuo^bVc41 zSc>6KTpQ}ymH3G5-e5fdK=gd;1^5-}Wo3YHszF^pmsu~rJgtC$0fq1p3 zOL2(D4KfI)RCXLs6>+7d%QBH;b9E8aBM^YiHz`&v4P9tmRQd5MT2)D)x!gKo$Ni7&S65tL}V# zNV-|e^rrCWwHy+wPrZ>$5QPEg9A~_Vw%z`=gD}0ecs)GcMA_fFb)Z=1nG?+D&-$un zWK#pXC%2pc2Km&%TqDVu}^# zI}-nc)=$@eZp$pOrAwfIyNv6k66yCCV%R&hHf}xCY?o44mClT%+X*@_z<`TsJN=M4 zmK5_-5B*``o3le5yI%cGB^ClmNS*!u9=T_ke4yOi7lo?jY6s%HlocgdLFQg-CJ=T; z8C&XrL!s~d?C1Sqr&=~KAwJgTEmQ`wi(SKW3d+fK+av8U99PAWp$RS@9nvR__zaW_tJB{hu9O)9bI*xWGMTSAO~4;gIoqhqyxeac`^d6|Jh^z@5?cGd-a?X91?B#vj!@v zu$-m3zw|@MX=r8uym*5!` zlEjEU93+RKlK7`C%aS)RdZT?$$DO_cwH)j@3e-G)wr^r4y zufMs*jU*W4MGvZjF`MzddBE_e5JZr+5d;EoebQ8>1|meMnh*bIq}YRFIcJ5WSz3bQ{KP|#mwIOL>3j>cXv>3Bv%M{QQ8 z>3Ema72gOu#RJBQC3432HmdS1S+g-T;G0#V`;`(uNWIpXn%r4YGdrES7-y<4@K$(4 z9u^<$X7c_WQbz{0Ljn7_gB$^C#LPI8EKnR$^H@F{6mxRr0YC z#U9mQ?XvT3C&`?Fz=`z>sO`k%lD*41US6#QrLWaSh`b@yloaM@nqk$Jj#KVu9~zB9MF9h2Q7n9wQhVO!NAf57fge)yUw75$b@qxKoZ>IZAo~Uv z?j{`ck|<(g%29!ovfmE;C>?ZWaY=Jq3mCfp(?l+{v#7cu)9$aZ%}Yq(egZmcDEej_ zx1Vakcb78+K{w(dhs(H=Uw2pMESR{2*O@ouaQt~}#6$^p{aGyetddK zGaR05yY(S<`V0n~r~Xu3e3JvjMRSXTy1Zn!O^WUh+5LA=3er)Wj(=2z{XHx`%LR_` zt$)DJp;Z5hZ;KLJ#XRvBds;d7IdY^Nxdtt8CEG4y4^DlcII5fzuYpl@m8nzlEebWs zI0P{)K|fI+xD8F9n@hb09b~tE5X5NxMuA--c&$wIHEz^%kmTw47^jmA;^~`vUpGgI zxZ)28Ll7^n)?(?hqCM8!Fm9~ak$28b-HPQptsxLO#3CZWTxosiwq&fE(8&otd2<~) zB<@&MI;;r05P8NX*UBn_ZXPo>7YTd(1{k>cuh<|?y_Z8MtO=R#F>F_FUKV7f1Az>%p zHH3Kn%kNhB+)aypBiEc6OYX5`IrPkZz*ZLX8_giy5nbL+bQjj?4sXcHKxB%8S}NY9 z1;U@Gbb~n9>Y?!RQ3zcwQQT~XkcB{<^G4M3X2{LoIE9t)@wR1E{^{^hdSVtM>pP>j=kaGeU! zpoEBPBX7+@UFeokC;@S>^10rAVb!m%WZmkk1uHvJ^M(=fi?6*5E=Rb=H}VMft%&_# z5*TB;j`=XIrmpRpQft--X#+x`kjXhC8rTC7O6(}5e5hpTR-Ci<%+?>p0{*$nIOzZW zw>BJS4VVb+aW)6&`hAI+*~|_K+s~mxC>ntJQJ!2Ak=uDv@=$KEqF58V0I#_FU;mQ# z&l4d8ej(yj2~lU1gjG=|Tw!NO7oU%=5CRFG^y`v$XwXOVFh$FK{SZ6@CP@;}Z8;1FEC z`Tg(1_j+IM!>sPr-BYWoy3Ve1_TC+>t}2I%O@R#n0Iq_(v<3ixkf$I36CHUla{Fw9 zJYc!V>$?L0-uM50paJL4R>+Iw9x{3!n$9*JUgmDrfR~pShrN@7yQR5{HHWjCZSIjM z1pv?h3eu8V-g$@lK3SC7b5Gr$+A4ih2pa08mr${=2(mmTfZ+m~7*r`9u_1ud!9@}# zK=K1))`x^_)kG2`$t9)7#JfgLmt4<)$wFY$#)QL|bn-^hirXsKs=TW5_~wC|7?R{y ziKZjl*y@A(+PyElnBabYa<=iZB*}f@_ zONl;Lv}={neeD^6f=~O#hE<12vYJGoy}wa~q_nSdX~pp;2Q@DAH!p}zJ_AQzGe50- zCMjOVv+q@S3*PYTORy;}1PL`rKZYe!(VePPRqQ6e6Dh``M#F)p#u($3n}WF%_tdgl zr_TC=;th6oD-WX>MYq_2RqXFIiBD7rAL|pQSpv(C+3q%PM_4{BciHty{#^g58gL&u z$r+??*6Xp*=v>uIopX}30HIl#a(PX-ZpvZHw^CHM9DS5qc^F=PiNywV)VqG$jmd;A zejjMegeHFJ`J2UTSQ^BS0wM+7@mzlesVWNSXK)vkdp&%j8@HE=C7+#ichluc{CD+Ug>Q90DRcbVLnT$L)1hjPny) zu#G|VQKZtIp~@!XrW}v=7Y_l%qQ!fvCe|_iWnJ?HK3cj-#-isAqDI31nA()P?{CZ* zrh_b@yGpp2^ll{rg?hq?eC98c02kG~N;?y$e;(^5bU{)wd{g#duoTB;r?|%CFJD4x?WE-E?O+?Y_9XtVPG>k-$HA?`|*?XP8jjM5^xbm`@2rOTt%zPv@jX)4yR$rW_pQ#b6o>f88;-13b&gmoM zV?dn9!OjI))nP>W<Cts3W zat^ZNqm{*h%Mx2O0{_oXwZg^u-%uXq2{lYS7Z>QYV3UdaA~iXVe!Yedm3fs*e_Uht z!lWcM!?_}*Du?AGnpxD>rjkI;*tpQFxM%FM#Nd?z1_54J-v+)H4HTWu zr3Fxx^T)w_0-rEKIeRxqUV67?pZk8co)aN?`o(Ac={FdLuwAwC&nkRD{C*J2M6_D? zAyM&~Uu&>gkV>9V9FHvlZOYVJV$9p_dlIkS``K8ffA4l6Flwh z|H0S!S7OeyT;n8#xx6Lt+;(w;l+1z=YAJ~pRF@gs2{M9>l6|u|Zdc_gc-gU>}Ptr=D;A$6}4^h40Jj%%(fBTSHGGSEWdhQ*bPTpM%iJ*zrTgk z5bS9|f4^iRd8+v_|D=J8_OcU0O`$eX@94Lg7@S#@D2W8_(<7&a5iJ+@RecY;KQhLz zsWK1{t{gxaWJWSMhR$W`z`)Z&Koa;tQj;b#Ho6@PBB&s}t+4=J8+N!4f)G~4?cvKB$T`JOU7>3aoqaRPs zf}jpISDK!hw-AskSJoqdz`fpk1$ec+z-4~i{AlT4!_V*r2Nq3B+U1Hz9Rg}&8pyH} zwB@J{7rFcpT|joYb0jSM8w*8>V9$nzc*5hw`I2M9uc9;G&r1;|;533dde0bO`)g0@ zGqCQ`*S12=bo^CpdXZMw?x>SXbDm4aUh&a;ZZ0+`Uks`;L00xplxs0YM{YQ-@-;q| z$@}GG{<1btv1;aXY`Czh+<^_j8n7`4B)))c*mfi=K4pz%M=Jh`luaOo6aDh+>*l~* zpkG|}5)0+zlu4SIZyxf?Va&(mNq}!;DSZ~yJLsF0Xx)4t{00>c`ssPZOJK-#(v7i< zSy;bT%TV@L%%-PN;h+aJ5E#f=msI8^iE~-4_%R5z$0I5GkT3{34YJEG=ecA~mYO zn|$N&k&}Vxuh-RLM|!j^x?f13E&K6f3?3H?z5x&e&s64Ki_Z&7e7W60O|2n+X5LW`M zQX}q_kMmWo&THbsS6|P{PlA(}kclP#!p|NA8?~lnobzJz1zCvAh&j5oCNBF?#272+ zQ4I4g9kD%(pk(UxZxQcmaF+ajQIt4!QCs6l7r+=?7c${WOPsT|)|Y=XF2Lt@k;bC7 zI`qX9?plzjpAme1xZ{!J-28}Vcjg4-Od1Zk>tDZ@zy*jagm`e-n0D|~X>_C{X8dT-4MEgvk7yG5Z$%0RDfE%M1KY`vg z<^JPh-gcd>Q==gljW5uw9YAzo7wv)TIr&AnU9kvx-{N7GX!?*I>W7Ttcsi-b-LE~B zH#EM)lNiYAhT@bCANFu&izUiCI5H92FPCq1k8idbx54?8i`q4OmKShPeqlZ5djmo^ z4O<;Z-@3)tl|hDa$_Wt|52>9kpS{moCfu9Lj3><#M?ns8E`IR6_iNtLqw%I3=7+#XLLXolof*Sc<;TjTj!m2WC?OSDeO; z#5pF~ai)w0h(`Mob^Z)Y7b? zLn`?(<3@Pp@(}~uoOWZgHo9>4uk&Js3W!TxD^OUF2rk)$jo9>5KY40q2vc-o11~q_;1V9;QROzbzHQJZP6<>3myy=8XB6&s!OU1#(31P@ z*&pZ~(^!GiwpJ<sIgoA}I7dQTM^SUBrRdjV@oqCZ z_tEhM6mL~?o~8KeP9bNxH;O;hK+tRPuRgXF193T>hA}lXeeYBI+sYq!w!D6QWsA!) zwa!KEp0=ou5fd&WY)QXauBmKEq&Efom-kh8>OLHBqH&q%htAQo$)sjZ~IfbISrcKHAFDrnBFdjJY zE44jNyTbz2DGY#3dy#`B{o|mAOkd!v)m1Pkt%Gf`bA{6;cPL%ax+H%n@N>}TqE+e~ zG!I5DS;Hh(7GQrmGFa?IYFcuj$MhLHxcb|J9Q})t%h*+jm;o@^ZHeEXS&AOEdsu#y zR*CN=c@O4N)yjsVH$fcsZ*4yY&SQU2G5(8b7x7y@5%I|?^~+La;6eFlr@A91(WZuz z0~=$DY36+9E>}O|I9eSe`m(t-w?51cyxex+QCKU;c_wbw|zCP?zf zl6gZ1ip;};SEiEOL?|>=c|1*;G#&I+*19!}Pp!>32jT+N=HyB%?q~_h$^r-imWf3?Z2hQwpPM4TWCtrjlI?%j8yydCk8+;vyVBw^L_g{uv> z_&m!;Qh$ahWbKfgCX?|7@4Ap49vsW)0xd5aP( zd|s@o<9o4CIGZw&;;H(rZn8N0ztJ$JP3t$MHb3te;y{-CZObOc z&49LAl}rR5848M@?~W3aJazup#za_9N^__x^L(cPeHs`60b5o!zNj9SzzEgTrZ~tB z{^vO7!hGibc_wQF`Zq`Yr{62V%h6ifp8M+R{JHEL8a=io0ir^qL+f!f`m}Dyr?003 zK)X^-IIbZ@%y8^qIj$2QnX7Kr;Z{1=)YHwL>%HtJ0MY@1ec=3M)IuLOpcm6Q)`#t-Zq)uP$@4rbe+H|iEINPa?61L(#n`++&YL2E?x4|ri-ks0 zSCQY9O}^%@8m765M%kUW^n6bvB@<`j_>W094Y<8C{(bm7lPyN|etgwo;-G6__xIRK zXTj4ZqINQ{c zpPItv2=N2~AnJ+eUzN;$CMT=RAAr&iC|UH=sQLeeqIQMj0^9?mZ8a;zDXh3ufH<%% zfaKR+b?qD^!}*#}Hmh_z!ALbsvNBswIbGI>>ya@ah2U=@FbBMWAqnpRws@=wGTW_) z2iotwt+rX|U%UPA@4`1bHAL8E8LZ=HegJ&9s z7UNQcvYGxv+h<)e4FwDj8lRO)pRjHM;J=o}j!~H>NU)1oOgh4`w)N#_R!~Q{q$)cW2>3zw&sx7Msp); zDy=@3ArKlb$q6W557qBnNGQ$~_CPtE%lOX(5N66cqK2=Nhf!=}Z^X2hxWUU~<&7Tp z76P_ZbTk#v-^Ak?QO*zF-C)XR+t5_L*DmmG)`B@O7mR;iiX42Sb7Xzu`{qQ-UB~7v zGls31ss8ieGJTu7!ZI}}9!Z+J+!X%T+?9V0to3YAmPW9aK3B zY#{cWsqO%vT#saDE;c~_RfM2zS}{8C-Il{|?l7u_N8y~pKsL+(G`LAU3}=obGfFA9 zRL2HTo-&$}N#R%I7fNuA?`O~9G&VkOr!erBjFScY-OIi{3jJ3&vSX)GIgE~X<1H5o zd(PqlTfau)c+sZ|wG&8;ouvY`gmu!dObM7Z>QYTR`zHxrg8&*_Pr@|6H}gB+E`?+Y zNz`s+kjVCUMT}}Bt(iG20gcipn*>EA{paN!8yN5y(%X&ZYbVHSZSymDy8OsQFN5A#cK7FAS8~x3 zY$S1|>GR#CENCR}SLGw)FiW2~od*~JKcJE*CYT5Nq z1hT5>Y2Q6n44V#KiG{IGGxC%QO8+&gQk$x}=+#=p%m-jpgD6np3ScWrdm*_@_uUAX zH6}{w z(G=dKgEu+*ky%gb2hhIKz0ic(EgrZ62hbWtYdYd5Jhv{5e8;rU0Q((18bQSZi9`}k z;UUe)%p5j3aa@IOoS?dF*6C>@bV=^c2WoA~lDFdx=L-Bf&-!9AwO>7Eh#Zy@0dog5 zT48U2hG|kxrotCcwg(uYu9I#yrrhu{)LUA6faV0se(o-PR=-ENIrAfd@R^R|G6iJ6 zoc-4K@3XZG(Sbg71`jX{?(aU>R7y>O!uC-ArTC?H1?^{|fU`m+fh6^RG9<(RaQ2~# znGEjOr)3RfII%^fCA&WkL4WLxVpI+e#K{ zc~l$x42wZdTCg@XWjEA494G=W*{IC5blhWpg~`wD{^+(l_p;k-{hlsM00Ood} zMcF-6z)V~98f9)`T2ZFknhYM?Xwu*?;Fs=ZJdVsOEpE_P=Z9w@Ma*Z6ig%)H?0{77 z3=*35P!T+Sx^Jk?+Hg1>(`w(#^xai8S{8egPiF>sKsVkiX!fn$7;CG*J6zb$%?2f? ztrG*cn!ih+%fzGXf1eD^xgz9f4;VQ2^47MxxX7# z-XRC-2A896%Dc2Id%`(yUqA0BPG+(H``W=~qCx5oKZN()rpI8NF3yB?1>m}p{5{IG zy3zf=*OU-ri^gb{Ravdcu$Z&?K_>|Eln@xW;@ zIZ+?Vdmxy_{>8ZOiEhfoy_Bvey3M#bc2kb#jx17RDO*q$WnPOaT10#U+6Q*_DxjYx`NC$m})H_OQ$!T66q2J09cX`hzJA#V6Xa@ zbO}A5Tz6?VhqDC;~0;zXmGI6s%SMNnD|j6DB;xW%Sqd zxy0{y-?o$+d%A{yWOx5fNy-3Df(RJijs7&W6^*5~o%)I&vPTy!0*7JQ7_r}#^V0tm z6|{Z86q!%?oXX3IR#Z7_m=}bk-SZM69ANi`;reM&-Mg23h&0zcc!6J{UroHtMF zVs#JH;MXPs`f!2TsLC!1oG$O{{ zRxBt$>QTE45By~J;_rKYPUadp>M%@4x#m3b4cXPmXqu;Pzm|Pr+ua-GpF#&FAer$% zi*C2=m~QfqN{o3~5dZ*H`_Bu|eNQce1J5Hh;WNpRTy#7NM2%5=J$nCMm5O#vnH7!C za;!ZgSBwyT;UtCSJ>1YqJRfU2If_VpHj(K0E4{Olqp8|=V43faG?x>z>jLCNWxo7vVTq=0npogZnXOOi zr8<`Ke@VeWp8Ul#Siz(WLB$oGlp?+4w@+-f%$VuT61?fKGqdT#7)%u0hp zzZ08pK>v& zt@6RpQZ}GcV?Yf_$!s4nj-$E=!y`JV7)2+Fo*%UA1rJN#bsjsD0rrpxv(e8Es!E?u z#B+npPL`&mcM9l?YZRoqQS0N_y}(HYsl?A0J|hX3X?$2Gy7S4;rRy>9+Q{>^`jI9i zMU5m~lEYmIV5amg*ofF`vsYhGCMm$55FTZ4q()JOpD6HQ-MAu?8ptztUywXKL%ELq zvyB1JZL-Lm`})n;$&{725Z{smfKbJCyxIP<6n%BJ*HwnTp`!}?d?7c&gJ^RMP$oU3 z#1iY-EPp*Oi?c@-^X~3<(?B^^=p*LM?j(v!);p}Zg(a?^gQxEXdFdXeRZF`~N~`#l z_H2;}b=;~-(k>e+&f&*Lp427r^xire9YnMdsNW`fGcA`E7S5*PiOIKVBA1yPbl)~IL7=}@J3wfR(45$3eHnHpKLz}%FD-o}rA z^vW?FurChyy%IHp^E%oRs_)JS;rDy^VScg9X%y&<0E8y&nq%v2AR!=FVR2}`{52P= zUpPh_*zj&~{?z`BzoXl$t7*!uS$YRWNXnd1KI$AJrRCLY-ayC=gpMh06(7fgmoMxx z^xC}mtFI2Be3QOMV{XjE+kf2k{ZHw>FWM;l<%Y~=iAlis2cWB1pzrCc=xA}q&G6Y;ZBZd_{iou> zmA^TeokmGtX-jq_{BJCJ+Rzcc6`(1ywM%sCd1^(rARI8(^;{9X(bn8RDhfmQJ0g>d ziu|>%BeuPUI~FtrKB0Yey6XGc@&;GH z`zMm(JaeW2{xc<@s=^8er~w25vd~!g=e@(~C%_AXe+lh0bWMD>PQ7LhLpi$dAecPs znaSce*3cvP@4ckxuD8*P;Rcd82)z1^({7YsKH)=7<@T$8Gl5w}D=O=Lef48j0LEq! zUrut?ER){_~FPucL*fv#_z!aBz5a^%}gvfrsslUf`gh(*^hCr7w-JP2cGmmUvg2_oWap6UJuPwiGi@=o2*U}Ys~;> z*g0V%@QN$*QxMv}fvU=w9Y>+UxX_3 zMpb@1Ldsi#5F;-WHS|L0R_?leA*HRr&iC%y)1MrtM96*6o1l;%xr)?bH3Y&FLS$#Y z{(w1ZnD?t(N1?$wi7Mu=Y2l~#Kqa{B=`e>o9-=BTbltghDO=cEmOh}MBHpXgFVZuM zJIM{A_Co?t9LxG|0bk880ZUv|;ClD^TAyOl;QLAN#`pS++90Am$Y;SbPuky+EuOQ- z+Y6>1It%Zr#viq)$lu`twkfnaNJTty^)e#0(kD0y$u4(ZE;c$gm~$_BX9Uj>a8;(k z&XJM*z4&XJKUxw}qo6RqB?kF)jT)eyNk*bz^r`gMT1=`1jOyr9mEY!DqdYj+aFTSV z1XF_tTdJ>K+pJ=cUfsROPse5=i4At;2pxavv*bb^0CbUD9FONm#<{y+S_0H5-Je#9 z_(^B9-W}a~{R)^BHvquB5I4?ocbN1`bRVxHKg-KUN_F0 zXw;Q@CcZDrod44k<+tOoE_q>91V)Rdknk zw&73bV_C>QRCs7WfzMRD*`Fx#{e{q5V$usnvw}$^g=7$-3R>h`wBjQswbjH8#(DRj zSqQ0J3d3dpOvqC1<+>-)VCGq%L@ulByPx~qAQdWM2wU*+h#D*Vgs_icJUHjenTlY@ zM6tyB#~3V~go4TEp~#E`22yul=oTX#`2G~CD>r(cmvDW!>bX^4^so}`k(e$&VKYe! z9QAG}mOPp_08V7dt35h&sZry~-2@ksNa!C%636Jh#wW%Tn+$@zOm9ajy_%m2>1|3) zz38*B*So{TUn~;(VyUB|q&rfFK0SK|)L0djCEZ^j9e27DB)dE(4A;&H+L#6k1YX$% z{D}q`oyo^D0TulZxTIGgAyK$bf6TW+U2P+(MNy*=xF1;FqjPG-=h}p^z1@Xl+E&iZ z8L1gqnn+0F7NHf%e`D{;b@)vPa0gjBf~LxJG_RF+hwo9Gh~w#&4q|Y*j(gmM{-WXc;cEO*NW1Ib32F8bmRl z_bA7`_U{AbqXONrU?6kPPwImDL4o)szD@^+N$!vd)Y&(olQ!f>+m-rq?8pH~yQ~~U zIn>^vAu=)i`^+~oFQZmJl(EqN7i;GogFVXq(r~<&Q323J+@dwmfq#*{5T8La&LA#qns`#UO+K?_Avja1N9sQ$g;Xv{baph=f0Qd=> zfwZ^YWz*e}H`;+-aW7dNyasQlCht&>Ua3T>!ZRBq||7zy(tyFWt# zHYpbjL^4-wc0X`hc)xx?$DAM)J@Pc>{w0YdcP+4PDLm{zP*Fu+MYRk9!jx9*uKFmpI&#*L2zW!Z7 zz-S*?$WaIfM#HN>2Ptx7kPVIz9=sUFwmMpM;(HlbD38t@h$p#}}flpg&lahEZ{ zLfB#FKl}HEYg*A@G^#iu!u-`e&K3imkrjWL#7S@KP{f3L5VQNgGh2-3p*|h=c%g=# zY4QJU2Wz;wJ3SJ=zh*)|&Gq&dA$=|-q=3`cp9y(~NBySg*X@`Y;!5EdX5^s-j3@6b zOe|A6eQBC}dQNKMGum^7pc_z3Zmu7brX$YYZy&(U1n2nGPtt)*Rq94jm}$SagVqO{ zmk1Y(`~;=wzy^R~Tp_TCGz!9kdLW-T?^M9XF~6nYUVXk?^9TehFi-3)1~trz8#^|{ zOdvA;cyXjY(r!4zG)$3 zB!r&HslFk}xje7|7TgRsCqy;<(Gb>PicYtjS$JFY+FMHUOsE6u?5!dp_!)anpRNfV|O_q$s9SeD@3X zJd`2urbQA-uw@87Is#XBS$O;LlE@W_inL%XMjy2z!5SKhXS3mpewNTsMGCopj)+Iy z)N5xB@NN`#uXD_&eunHDS8`Uc*}rF=VIzH?cJI!dH@oQ&UdXoe36a7lW;A2l6O~G7 zUGqTP@(PVI%8B8%_VZf2I`FrA`8+GX&8ueO{gE2!g_$x+#JfK}FE^Aoz6(JLUc4V> zdu4MUNGP=7Kf9+4I|e~4?EYxrBMQ+UdldSah|igOi#DT>X-f&q!89Yfm;+3dg@!7D zF{AF@SyOEZ9k+wuQ{a^&;27&6M9zDky@||6hRCq1D4Lu zg4*a|-nhztVI4%^k*s)YPxpnKcXK~S-k>Vpo;jE3$iQ$A1Z5I#Tn}J488Etb`Q&qy z_S$x|9Ro^rOe=pNRb&ip#32_Y4Ux$5jI9sP5~!Da4qb!}MSF=VRmU0_ntrr*z%ZuZ zK~9&80Qp@w-EvB{t4?EUBj=OAySJ!~z%2BCH7W_p(>pvmin^@O(O7{`D1M%2KHiUGj)Cc#`K zTNmn2HM@^1DD$EI+gdL8WI`-DpUjl)EgE&wjQJ#6zr?g{HVl3HR3s zBv`A3Z+R&qy7!QZAIm{Xf25uJj$x=ND%j?^jfWM|{xtgO=`4RJRWwM1@Jy%jBfwoc z!-dXXQ^cAh`k9sxDig7Xw1z~Y9kx4yX;9gdo4C*Uj`H+02ZE9LCRUMx`I&c_|J0Tm z?t6&p$>>j|kV``WP}EKw6UbY{@nxLLkNO?Acw=0*=K?`g2qAlsb7B$?IZdFcfeBGm zg$$K8nt%)y;B%P+aVV)0ZdR93?UyQ0X!lF!E!#+B&iPi-iw}**BLii%oNI+a(9Nf`_9Sx<%nU-04Niaq%#9ZdQ=$yh_IH+9hg7{;s9 zh1GkAo!Yq;^-$$@_ZE+G=209TT818m@yEv6q%uz~$Bhda1F)`frj2#U+t2cDcq9Bl zsAeUz@RM-I%3lYH*BUGxmy3Mht_rSwVy-Sj?npjs>-uPzsow!WXT-=)QyO}qNeC*+ zuyzJKYNlmRobwYFf2E&%(nA^`L&GG`X$o&c;nWNKA8M+K40CvR^`whh=pV5{?YIG- zqv$;ESMsJLN)y&TcTc2YyU3mq(io&28}BIo&z%nDMCZ~mzf5VhPg}>3;YF=z#=P+C zlOP0T!0QWpt5@C~4WaJWS%6{4&1BSr18Vrprkx_fo3EXQ!&Fx{`KOknY3k?za8SeL zZVug@%qt5>KU31wuVes&Oalq_DCk_0#94EScysn1Mc}bo0+0h4uv#mQg`D50fni*~Sw({j4fYpBphz18zWV1BxCJl#S~#wtG#vGv|QDDlP!TSxY90 zRD9E5W04Uc7m0;D;-L6_KERYWP+5C(CjBN=BAqCBgHxi7jgzH2rOR@cCGnqtaW74` zO3Z66C(l&e_p7AqHFOC9m`)Cq+b=i02=<(SKrfO<3*Qg682P^T??T;TVN~n)tnBzq znj`C_UQV9ZT3vYQ*iIsDSq_)tU}Uj8Dj4!@&JF*14Azj`Fw;_G?kjyV200)>_@{3R z5Byhl3?F6LsHY$cTBN;E+y=aXb095CLVqsa`9A(mdUTZtUaDV?uJ_(&XZCTX`Tlbb zQiAwoQDWTR3#S7BPWUOY!@=h}yFb$}A}Po=)mS06ZXMCE1-LNP$rq~F_|%G4*2y0@ zDu*eDQO0W0mF=`J7~!Dha(D093HdvP?)<`*2Q6&?{+JE7y<8hW#EDYfVW4<5Y_u!6 z&eXQlxKi_`h~!3(zX{Zj%`_)+{TI+mRWDy-K&N+v5 z`bnB6Btd!=9&a}zHyJRslHj4T>-t-CPAaG~XlI3{c z@nI|S5x?3Od=fx!0vt=8#$lIWIA;XQW0yxYeesI258D12nQ2HBg-XR<_to^BcEl-~jM)-8*9UB3iR#>`&gQ&Fh&^bL(2$I>t7YG3Gm6Uq zE*lbtMQ4ubXz|8zJosnj-=TX==N6=ap-O=L$Cl}P;EW-=Fb)7pJ>(015$M*IK& goR5z}#rx)I9Xl5VuRF9Exq<-&8CB_8DYKCO4
- + {row.approach.name}